查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1836926

可吸收血管支架市場（依適應症、材料、最終用戶、支架直徑和支架長度）－全球預測，2025-2032

Resorbable Vascular Scaffold Market by Indication, Material, End User, Scaffold Diameter, Scaffold Length - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

可吸收血管支架市場預計到 2032 年將成長至 16.6585 億美元，複合年成長率為 14.18%。

主要市場統計數據
基準年2024年 5.7657億美元
預計2025年 6.5695億美元
預測年份：2032年 16.6585億美元
複合年成長率（%） 14.18%

對可吸收血管支架的臨床機會、工程原理、監管格局和相關人員動態的權威介紹

可吸收血管支架代表了材料科學與介入性心臟病學的融合，旨在恢復血管通暢性並消除金屬植入的長期存在。其設計原理是在血管逐漸吸收之前的癒合期間提供臨時機械支撐和可控的藥物洗脫，這可能會減輕與永久性植入相關的晚期不利事件。本導論分析描述了技術發展、臨床促進因素以及相關人員的生態系統，這些因素共同決定了臨床整合的步伐。

臨床醫生、設備工程師、監管機構和醫院採購團隊在價值創造和風險降低方面各自扮演不同的角色。臨床醫師需要確鑿的證據來證明其在急性冠狀動脈疾病、慢性冠狀動脈疾病和周邊動脈疾病的安全性和有效性。工程師追求更薄的支撐幾何形狀、可預測的劣化特性和最佳化的藥物-聚合物基質，以提高輸送能力血管再阻塞。監管機構優先考慮長期追蹤和影像學終點，而採購方則考慮手術成本、庫存複雜性和報銷調整。這些因素共同決定了產品開發、臨床試驗設計和上市策略，並決定了哪些支架概念能夠進入常規臨床應用。

定義構成可吸收血管支架模式的材料科學、程序實踐和臨床證據的令人困惑的模式

可吸收血管支架的前景正從概念性前景發展到實際工程和臨床改進。生物可吸收材料（例如鎂合金和聚乳酸衍生物）的進步，提高了其徑向強度、分解速率和生物相容性。同時，器械結構的不斷改進，包括更薄的支撐桿、更堅固的支架幾何形狀以及下一代藥物塗層，緩解了早期對支架血栓症和血管回縮的擔憂。血管內成像和操作技術的改進降低了支架部署的可變性，而從藥物釋放型支架中獲得的多學科經驗也為最佳抗血小板策略和植入實踐提供了參考。

不僅材料和技術日趨成熟，證據基礎也日趨完善。上市後註冊和重點隨機試驗不斷縮小可吸收支架能夠帶來增量效益的臨床應用範圍。監管方法也不斷演變，以平衡快速獲取和可靠的長期安全性數據的需求，鼓勵製造商將長期追蹤和影像學終點納入研發路徑。從經濟角度來看，醫院和付款方越來越要求明確的價值陳述，以減少長期併發症並簡化終身影像學和干涉措施。這些變革性轉變正在共同調整研發重點，影響報銷談判，並縮短從原型到臨床應用的時間，從而顯著改善患者預後。

評估 2025 年美國關稅對國際可吸收血管支架供應鏈的綜合營運、採購和創新影響

對醫療設備組件和成品徵收關稅可能會對可吸收血管支架的開發和商業化產生多方面的影響。關稅帶來的成本壓力可能會增加依賴國際供應鏈獲取關鍵投入（例如特種合金、聚合物原料和精密製造設備）的製造商的採購複雜性。這可能會導致協議價格和利潤率壓縮，從而推遲臨床試驗、生產規模擴大和全球市場進入計畫的投資。此外，報銷談判將擴大考慮總護理成本和生命週期經濟效益，而不僅僅是單位成本。

應對關稅中斷的策略措施包括近岸外包零件製造、重新協商供應商合約以及重新設計以提高材料採購的靈活性。雖然這些措施需要前置作業時間和資本配置，但它們可以增強對未來政策波動的抵禦能力。此外，醫療設備開發商可以透過加快開發成本效益高的生產流程或優先考慮具有優惠條件的市場來維持商業性發展勢頭。臨床採用路徑可能會隨著時間的推移而變化，因為醫療保健提供者會權衡可吸收解決方案的臨床效益與短期預算限制，從而在不同地區和醫療機構之間創造差異化的機會窗口。

針對臨床適應症、支架材料、設備尺寸和最終用戶設定進行細分洞察，以塑造治療途徑和採用

細分視角揭示了適應症、材料、最終用戶情況、支架直徑和支架長度如何影響臨床選擇、裝置設計優先順序和商業性定位。臨床環境基於適應症範圍，涵蓋冠狀動脈疾病和周邊動脈疾病，其中冠狀動脈疾病進一步分為急性冠狀動脈症候群和穩定型心絞痛，外周動脈疾病則分為跛行和嚴重肢體缺血。急性冠狀動脈介入治療通常優先考慮快速輸送和可控吸收以支持早期癒合，而周邊肢體缺血介入治療則需要長期徑向強度和增強的抗壓縮力耐久性。

鎂和聚乳酸之間的材料細分在強度、分解時間和生物相容性方面存在不同的權衡，這體現在器械的操作和成像性能上。最終用戶細分，例如門診手術中心、心臟中心和醫院，導致手術量、基礎設施和採購週期存在差異，進而影響庫存策略和銷售模式。支架直徑細分為小於3毫米和大於3毫米兩類，直接影響器械的幾何形狀和臨床適應症。支架長度細分為18-28毫米、大於28毫米和小於18毫米的托槽，影響輸送系統、複製策略和庫存範圍。因此，製造商必須根據特定的臨床適應症和最終用戶工作流程定製材料選擇和尺寸平台，以最佳化採用率和經濟效益。

整合美洲、歐洲、中東和非洲地區以及亞太地區的臨床基礎設施、法律規範、報銷動態和採用模式的區域觀點

美洲、歐洲、中東和非洲以及亞太地區的臨床基礎設施、法律規範、報銷途徑和從業者偏好，塑造了截然不同的區域績效和應用動態。美洲地區擁有高度集中的介入專家和大量的冠狀動脈項目，有助於快速的程序學習和早期應用。該地區的監管途徑和付款人談判強調強大的臨床終點和長期安全性，從而獎勵製造商提供成熟的上市後證據以及隨機數據。

在歐洲、中東和非洲，管理體制和報銷模式的差異導致可吸收支架的可近性參差不齊。一些司法管轄區優先考慮衛生技術評估標準和長期成本效益，從而促使製定客製化的市場進入策略。亞太地區的市場臨床能力參差不齊，但手術量成長率較高，擴充性的生產和本地監管部門的參與，加上臨床醫生培訓項目，可以加速可吸收支架的採用。在任何地區，血管內成像基礎設施、操作人員培訓生態系統以及本地報銷政策的細微差別都將決定可吸收支架從專科中心推廣到廣泛臨床應用的速度。因此，制定差異化的區域策略，將證據產生和商業化投資與當地臨床和付款方的優先事項相結合，對於持續採用至關重要。

關於支架製造商夥伴關係、臨床管線、生產規模、智慧財產權定位和競爭差異化的策略企業資料

可吸收血管支架開發公司之間的競爭態勢取決於臨床證據的產生、生產規模、差異化的智慧財產權以及商業夥伴關係關係。領先的開發商憑藉強大的臨床管線，在各種冠狀動脈和周邊血管疾病適應症中展現出安全性，從而脫穎而出；而其他開發商則優先考慮製造能力，以確保設備性能的一致性和法規合規性。與影像公司、契約製造製造商和臨床研究機構的合作可以加速證據產生並簡化市場進入流程，而公司內部的精密擠壓和滅菌能力則可以實現品質和成本控制。

企業策略擴大納入與醫院系統和專家網路的共同開發契約，以確保真實世界數據的承諾和應用途徑。許可安排和選擇性併購可以擴展材料科學的能力和地理覆蓋範圍，但也需要精心的整合規劃才能保持臨床發展勢頭。聚合物配方、合金加工和支架結構的智慧財產權地位仍然是與潛在合作夥伴談判的戰略資產和籌碼。對於公司和投資者而言，成功取決於將臨床概念驗證與可擴展的生產和有針對性的商業部署同步進行，以反映最終用戶的需求和不同的區域准入條件。

為製造商、臨床醫生和投資者提供可行的建議，以加速臨床應用並降低商業性和程序風險

產業領導者可以採取具體行動，在管理臨床和商業不確定性的同時，加速技術應用。首先，將臨床開發項目與差異化的適應症路徑結合。優先考慮那些具有高影響力、短期立足就能帶來明確治療益處的演示，並設計結合影像學和患者報告結果的試驗，以強化價值故事。其次，透過多元化原料採購和評估本地製造中心來投資供應鏈韌性，以減少貿易政策衝擊的影響，並確保向大批量生產地點提供可預測的設備供應。

第三，我們將積極與付款方和健康科技評估機構合作，建立能夠反映醫療總成本和長期效益的報銷模式。第四，我們將開發臨床醫生教育項目，將影像引導的植入方案與實踐培訓相結合，以減少手術差異並改善療效。第五，我們將建立策略夥伴關係，將材料專業知識、生產規模和臨床試驗基礎設施結合，以加快上市時間並維持品質。最後，我們將採取分階段的商業化策略，首先將重點放在卓越中心的初始市場進入，然後再進行更廣泛的推廣，以累積真實世界證據，並根據早期績效數據完善定價和服務模式。

融合主要專家訪談、臨床文獻回顧、註冊分析與供應鏈檢驗的混合方法研究途徑

本分析背後的調查方法融合了定性和定量分析，以確保獲得可靠且可操作的見解。主要研究包括對介入性心臟病專家、周邊血管專家、採購負責人和監管專家進行結構化訪談，以了解該領域對器械性能、操作流程和採購優先順序的觀點。次要研究則包括對同行評審的臨床文獻、器械註冊登記、監管備案和專利出版物進行系統性回顧，以揭示臨床結果、安全訊號和創新趨勢之間的三角關係。

供應鏈圖譜識別了關鍵的投入依賴關係和製造瓶頸，而商業管道分析則探討了醫院採購流程和潛在的最終用戶採用情況。研究結果經專家顧問小組檢驗，並在可用的情況下與長期設備性能報告進行交叉引用。在整個過程中，我們強調資料來源、調查方法和資料來源的透明度，以確保結論可複製並適用於營運規劃。這種混合方法所得出的見解既具有臨床相關性，又具有商業性可行性。

對影響可吸收支架發展軌跡和商業性成功的策略要務、持續存在的障礙和關鍵成功因素的總結性綜合

總而言之，可吸收血管支架在臨床應用前景和工程創新之間有著令人矚目的聯繫，但其能否成功應用於常規實踐，取決於材料科學、證據生成、監管策略和商業性執行等方面的協同進步。仍存在一些持續存在的障礙，包括對長期安全資料的需求、應對貿易政策波動的供應鏈韌性，以及考慮生命週期效益而非僅考慮單位成本的清晰支付途徑。然而，如果這些障礙得到解決，支架技術有可能改變冠狀動脈和周邊疾病的治療模式。

成功之路需要器械設計與臨床適應症之間的嚴謹協調，有針對性地產生證據以回應相關人員的關切，並進行商業投資以確保可靠的生產和分銷。能夠將臨床領導力與靈活的供應鏈策略和清晰的報銷價值提案相結合的組織，將最有可能實現可吸收支架的臨床和商業性效益。最終，結合實用的手術流程、可證實的患者獲益和永續的經濟效益的器械將決定這項技術在血管介入領域的長期作用。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 生物可吸收鎂支架原型提供增強的機械支撐和可控的分解速率
  • 整合血管內成像技術，最佳化支架放置，最大程度降低不合規風險
  • 聚合物基和金屬生物可吸收支架平台的長期臨床結果比較
  • 成本效用分析評估生物可吸收支架的總治療成本和品質調整生命年
  • 亞太地區監理核准加速，將推動下一代可吸收支架設備的採用
  • 開發結合基因治療載體和抗增生藥物的雙重治療支架，用於預防血管再阻塞
  • 利用先進的 3D 列印和影像數據，根據患者特定的冠狀動脈解剖結構進行個人化支架設計
  • 可生物分解產品對血管癒合和全身性發炎反應特徵的永續性影響

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

8. 可吸收血管支架市場（按適應症）

  • 冠狀動脈疾病
    • 急性冠狀動脈症候群
    • 穩定型心絞痛
  • 周邊動脈疾病
    • 跛足
    • 危急性肢體缺血

9. 可吸收血管支架市場（依材料）

  • 鎂
  • 聚乳酸

第 10 章。可吸收血管支架市場（按最終用戶）

  • 門診手術中心
  • 心臟中心
  • 醫院

11. 可吸收血管支架市場（依支架直徑）

  • 小於3毫米
  • 3毫米或以上

12. 可吸收血管支架市場（依支架長度）

  • 18至28毫米
  • 28毫米或以上
  • 小於18毫米

第13章可吸收血管支架市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第 14 章可吸收血管支架市場（依類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第 15 章可吸收血管支架市場（依國家）

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Abbott Laboratories
    • Boston Scientific Corporation
    • Biotronik SE & Co. KG
    • Terumo Corporation
    • Meril Life Sciences Private Limited
    • Elixir Medical Corporation
    • Xeltis AG
    • Cardionovum GmbH
    • MicroPort Scientific Corporation
    • Zorion Medical
Product Code: MRR-035AB9C0DAAB

The Resorbable Vascular Scaffold Market is projected to grow by USD 1,665.85 million at a CAGR of 14.18% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 576.57 million
Estimated Year [2025] USD 656.95 million
Forecast Year [2032] USD 1,665.85 million
CAGR (%) 14.18%

An authoritative introduction to clinical opportunity, engineering principles, regulatory landscape, stakeholder dynamics around resorbable vascular scaffolds

Resorbable vascular scaffolds represent a convergence of materials science and interventional cardiology intended to restore vessel patency while eliminating the long-term presence of a permanent metallic implant. The design rationale is to provide transient mechanical support and controlled drug elution during the period of vessel healing before gradual resorption, thereby potentially reducing late adverse events linked to permanent implants. This introductory analysis contextualizes technological evolution, clinical drivers, and the stakeholder ecosystem that together determine the pace of clinical integration.

Clinicians, device engineers, regulatory authorities, and hospital procurement teams each play a distinct role in value creation and risk mitigation. Clinicians demand robust safety and efficacy evidence across acute and chronic coronary presentations as well as peripheral arterial conditions. Engineers pursue thinner strut geometry, predictable degradation profiles, and optimized drug-polymer matrices to improve deliverability and reduce restenosis. Regulators emphasize long-term follow-up and imaging endpoints, while purchasers weigh procedural cost, inventory complexity, and reimbursement alignment. Taken together, these forces set the agenda for product development, clinical trial design, and go-to-market strategies that will define which scaffold concepts progress to routine clinical use.

Defining disruptive inflection points in materials science, procedural practice, and clinical evidence reshaping the resorbable vascular scaffold landscape

The landscape for resorbable vascular scaffolds has shifted from conceptual promise to pragmatic engineering and clinical refinement. Advances in bioresorbable materials such as magnesium alloys and polylactic acid derivatives have improved radial strength, controlled degradation kinetics, and biocompatibility. Simultaneously, iterative improvements in device architecture-thinner struts, enhanced scaffold geometries, and next-generation drug coatings-have mitigated early concerns around scaffold thrombosis and vessel recoil. Improved intravascular imaging and procedural techniques have reduced deployment variability, and cross-disciplinary learning from drug-eluting stents has informed optimal antiplatelet strategies and implantation best practices.

Beyond materials and technique, the evidence base has matured; post-market registries and focused randomized studies continue to refine the clinical niches where resorbable scaffolds provide incremental benefit. Regulatory approaches have evolved to balance accelerated access with demands for robust longitudinal safety data, prompting manufacturers to embed extended follow-up and imaging endpoints into development pathways. Economically, hospitals and payers increasingly demand clear value narratives tied to reduced long-term complications and simplified lifelong imaging or intervention. Together, these transformative shifts are realigning R&D priorities, shaping reimbursement conversations, and compressing the time from prototype to clinical adoption for technologies that can demonstrably improve patient outcomes.

Assessing compounded operational, procurement, and innovation consequences of 2025 US tariffs on international supply chains for resorbable vascular scaffolds

The introduction of tariffs affecting medical-device components and finished goods can exert a multi-dimensional impact on resorbable vascular scaffold development and commercialization. Tariff-driven cost pressures raise procurement complexity for manufacturers that rely on international supply chains for key inputs such as specialized alloys, polymer feedstocks, and precision manufacturing equipment. In turn, consented price increases or margin compression can slow investment in clinical trials, manufacturing scale-up, and global market entry plans. Hospital procurement teams may recalibrate purchasing decisions as device pricing dynamics shift, while reimbursement negotiations will increasingly factor in total cost of care and lifecycle economics rather than unit price alone.

Strategic responses to tariff-induced disruption include near-shoring of component manufacturing, renegotiation of supplier contracts, and redesign for material sourcing flexibility. These measures require lead time and capital allocation but can increase resilience against future policy volatility. In addition, device developers may accelerate development of cost-effective production processes or prioritize markets with favorable trade terms to preserve commercial momentum. Clinical adoption pathways may experience temporal variation as providers weigh the clinical advantages of resorbable solutions against short-term budgetary constraints, creating differentiated windows of opportunity across geographies and care settings.

Segmentation-focused insights into clinical indications, scaffold materials, device dimensions, and end-user settings that shape therapeutic pathways and adoption

A segmentation lens reveals how indication, material, end-user context, scaffold diameter, and scaffold length each inform clinical selection, device design priorities, and commercial positioning. Based on indication the clinical environment spans Coronary Artery Disease and Peripheral Arterial Disease, with Coronary presentations further divided into Acute Coronary Syndrome and Stable Angina, and Peripheral presentations distinguished between Claudication and Critical Limb Ischemia. These clinical pathways demand distinct mechanical profiles and drug-elution strategies: acute coronary interventions often prioritize rapid deliverability and controlled resorption to support early healing, while peripheral limb ischemia interventions require longer-term radial strength and enhanced durability against compressive forces.

Material segmentation across Magnesium and Polylactic Acid offers different trade-offs between strength, degradation timeline, and biocompatibility, which manifest in device handling and imaging profiles. End-user segmentation encompassing Ambulatory Surgical Centers, Cardiac Centers, and Hospitals drives differences in procedural volume, infrastructure, and purchasing cycles, thereby influencing inventory strategy and sales engagement models. Scaffold diameter segmentation distinguishing Less Than 3 Millimeter and Three Millimeter And Above categories directly affects device geometry and clinical indications, while scaffold length segmentation across Eighteen To Twenty Eight Millimeter, Greater Than Twenty Eight Millimeter, and Less Than Eighteen Millimeter brackets impacts delivery systems, overlapping strategies, and inventory breadth. Consequently, manufacturers must align material choice and dimensional platforms to specific clinical indications and end-user workflows to optimize adoption and economic viability.

Regional perspectives integrating clinical infrastructure, regulatory frameworks, reimbursement dynamics, and adoption patterns across Americas, EMEA and Asia-Pacific

Regional performance and adoption dynamics differ markedly and are shaped by clinical infrastructure, regulatory frameworks, reimbursement pathways, and practitioner preferences across Americas, Europe, Middle East & Africa, and Asia-Pacific. The Americas exhibit concentrated centers of interventional expertise and high-volume coronary programs that facilitate rapid procedural learning and early adopter behavior. Regulatory pathways and payer negotiations in this region emphasize robust clinical endpoints and long-term safety, which incentivizes manufacturers to present mature post-market evidence alongside randomized data.

In Europe, Middle East & Africa, heterogeneous regulatory regimes and reimbursement models create a mosaic of access; several jurisdictions prioritize health-technology assessment criteria and long-term cost-effectiveness, prompting tailored market access strategies. Asia-Pacific includes markets with variable clinical capacity but high procedural growth, where scalable manufacturing and local regulatory engagement can accelerate penetration when coupled with clinician training programs. Across all regions, infrastructure for intravascular imaging, operator training ecosystems, and local reimbursement nuances determine the pace at which resorbable scaffolds shift from specialized centers to broader clinical practice. Consequently, a differentiated geographic strategy that aligns evidence generation and commercialization investments with regional clinical and payer priorities is essential for sustained uptake.

Strategic corporate intelligence on partnerships, clinical pipelines, manufacturing scale, IP positioning, and competitive differentiation among scaffold makers

Competitive dynamics among companies developing resorbable vascular scaffolds are shaped by clinical evidence generation, manufacturing scale, intellectual property differentiation, and commercial partnerships. Leading developers differentiate through robust clinical pipelines that demonstrate safety across diverse coronary and peripheral indications, while others emphasize manufacturing competence to ensure consistent device performance and regulatory compliance. Partnerships with imaging companies, contract manufacturers, and clinical research organizations can accelerate evidence generation and streamline market entry, whereas in-house capabilities in precision extrusion and sterilization provide control over quality and cost.

Corporate strategies increasingly include co-development agreements with hospital systems and specialist investigator networks to secure real-world data commitments and adoption pathways. Licensing arrangements and selective mergers or acquisitions can expand material science capabilities or geographic reach, but they also require careful integration planning to preserve clinical momentum. Intellectual property positioning around polymer formulations, alloy processing, and scaffold architecture remains a strategic asset and a lever in negotiations with potential partners. For companies and investors, success will hinge on the ability to synchronize clinical proof points with scalable manufacturing and targeted commercial rollouts that reflect differences in end-user requirements and regional access conditions.

Actionable recommendations for manufacturers, clinicians, and investors to accelerate clinical adoption and reduce commercial and procedural risk

Industry leaders can take concrete actions to accelerate adoption while managing clinical and commercial uncertainty. First, align clinical development programs with differentiated indication pathways; prioritize high-impact presentations where transient scaffolding offers clear therapeutic advantages and design trials that incorporate imaging and patient-reported outcomes to strengthen value narratives. Second, invest in supply chain resilience by diversifying raw material sources and evaluating localized manufacturing hubs to reduce exposure to trade policy shocks and to ensure predictable device supply to high-volume centers.

Third, engage proactively with payers and health-technology assessment bodies to establish reimbursement paradigms that reflect total cost of care and long-term benefits. Fourth, build clinician education programs that combine hands-on training with imaging-guided implantation protocols to reduce procedural variability and improve outcomes. Fifth, pursue strategic partnerships that combine materials expertise, manufacturing scale, and clinical trial infrastructure to shorten time-to-market while maintaining quality. Finally, adopt a phased commercialization strategy that sequences initial market entry into centers of excellence before broader roll-out, thereby accumulating real-world evidence and refining pricing and service models in response to early performance data.

Mixed-methods research approach integrating primary expert interviews, clinical literature review, registry analysis, and supply chain validation

The research methodology underpinning this analysis integrates qualitative and quantitative approaches to ensure robust and actionable findings. Primary research comprised structured interviews with interventional cardiologists, peripheral vascular specialists, procurement leaders, and regulatory experts to capture frontline perspectives on device performance, procedural workflows, and purchasing priorities. Secondary research included systematic review of peer-reviewed clinical literature, device registries, regulatory filings, and patent disclosures to triangulate clinical outcomes, safety signals, and technological innovation trends.

Supply chain mapping identified critical input dependencies and manufacturing bottlenecks, while commercial channel analysis examined hospital procurement processes and end-user adoption levers. Findings were validated through expert advisory panels and cross-checked with longitudinal device performance reports where available. Throughout the process, emphasis was placed on transparent documentation of data sources, methodological limitations, and assumptions to ensure that conclusions are reproducible and suitable for operational planning. This mixed-methods approach yields insights that are both clinically relevant and commercially executable.

Concluding synthesis of strategic imperatives, persistent barriers, and critical success factors shaping trajectory and commercial success of resorbable scaffolds

In conclusion, resorbable vascular scaffolds occupy a compelling nexus of clinical promise and engineering innovation, but their successful translation into routine practice depends on coordinated progress across materials science, evidence generation, regulatory strategy, and commercial execution. Persistent barriers include the need for long-term safety data, supply chain resilience in the face of trade policy fluctuations, and clear payer pathways that account for lifecycle benefits rather than unit price alone. Yet, where these barriers are addressed, scaffold technologies have the potential to change therapeutic paradigms for selected coronary and peripheral indications.

The pathway to success requires a disciplined alignment of device design with clinical indication, targeted evidence generation that responds to stakeholder concerns, and operational investments that secure reliable manufacturing and distribution. Organizations that integrate clinical leadership with agile supply chain strategies and clear reimbursement value propositions will be best positioned to realize the clinical and commercial benefits of resorbable scaffolds. Ultimately, the devices that combine practicable procedural workflows, demonstrable patient benefits, and sustainable economics will determine the technology's long-term role in vascular intervention.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Emerging bioresorbable magnesium scaffold prototypes offering enhanced mechanical support and controlled degradation kinetics
  • 5.2. Integration of intravascular imaging technologies to optimize scaffold placement and minimize malapposition risks
  • 5.3. Comparative long term clinical outcomes of polymer based versus metallic bioresorbable scaffold platforms
  • 5.4. Cost utility analyses assessing total treatment cost and quality adjusted life years gained with bioresorbable scaffolds
  • 5.5. Accelerated regulatory approvals in Asia Pacific driving adoption of next generation resorbable scaffold devices
  • 5.6. Development of dual therapy scaffolds delivering antiproliferative drugs alongside gene therapy vectors for restenosis prevention
  • 5.7. Personalized scaffold designs based on patient specific coronary anatomy using advanced 3D printing and imaging data
  • 5.8. Sustainability impact of biodegradation byproducts on vascular healing and systemic inflammatory response profiles

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Resorbable Vascular Scaffold Market, by Indication

  • 8.1. Coronary Artery Disease
    • 8.1.1. Acute Coronary Syndrome
    • 8.1.2. Stable Angina
  • 8.2. Peripheral Arterial Disease
    • 8.2.1. Claudication
    • 8.2.2. Critical Limb Ischemia

9. Resorbable Vascular Scaffold Market, by Material

  • 9.1. Magnesium
  • 9.2. Polylactic Acid

10. Resorbable Vascular Scaffold Market, by End User

  • 10.1. Ambulatory Surgical Centers
  • 10.2. Cardiac Centers
  • 10.3. Hospitals

11. Resorbable Vascular Scaffold Market, by Scaffold Diameter

  • 11.1. Less Than 3 Millimeter
  • 11.2. Three Millimeter And Above

12. Resorbable Vascular Scaffold Market, by Scaffold Length

  • 12.1. Eighteen To Twenty Eight Millimeter
  • 12.2. Greater Than Twenty Eight Millimeter
  • 12.3. Less Than Eighteen Millimeter

13. Resorbable Vascular Scaffold Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Resorbable Vascular Scaffold Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Resorbable Vascular Scaffold Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Abbott Laboratories
    • 16.3.2. Boston Scientific Corporation
    • 16.3.3. Biotronik SE & Co. KG
    • 16.3.4. Terumo Corporation
    • 16.3.5. Meril Life Sciences Private Limited
    • 16.3.6. Elixir Medical Corporation
    • 16.3.7. Xeltis AG
    • 16.3.8. Cardionovum GmbH
    • 16.3.9. MicroPort Scientific Corporation
    • 16.3.10. Zorion Medical

LIST OF FIGURES

  • FIGURE 1. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. RESORBABLE VASCULAR SCAFFOLD MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. RESORBABLE VASCULAR SCAFFOLD MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. RESORBABLE VASCULAR SCAFFOLD MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY ACUTE CORONARY SYNDROME, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY ACUTE CORONARY SYNDROME, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY ACUTE CORONARY SYNDROME, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY ACUTE CORONARY SYNDROME, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY ACUTE CORONARY SYNDROME, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY ACUTE CORONARY SYNDROME, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY STABLE ANGINA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY STABLE ANGINA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY STABLE ANGINA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY STABLE ANGINA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY STABLE ANGINA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY STABLE ANGINA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CLAUDICATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CLAUDICATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CLAUDICATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CLAUDICATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CLAUDICATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CLAUDICATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CRITICAL LIMB ISCHEMIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CRITICAL LIMB ISCHEMIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CRITICAL LIMB ISCHEMIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CRITICAL LIMB ISCHEMIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CRITICAL LIMB ISCHEMIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CRITICAL LIMB ISCHEMIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MAGNESIUM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MAGNESIUM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MAGNESIUM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MAGNESIUM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MAGNESIUM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MAGNESIUM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY POLYLACTIC ACID, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY POLYLACTIC ACID, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY POLYLACTIC ACID, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY POLYLACTIC ACID, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY POLYLACTIC ACID, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY POLYLACTIC ACID, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CARDIAC CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CARDIAC CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CARDIAC CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CARDIAC CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CARDIAC CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CARDIAC CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY LESS THAN 3 MILLIMETER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY LESS THAN 3 MILLIMETER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY LESS THAN 3 MILLIMETER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY LESS THAN 3 MILLIMETER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY LESS THAN 3 MILLIMETER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY LESS THAN 3 MILLIMETER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY THREE MILLIMETER AND ABOVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY THREE MILLIMETER AND ABOVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY THREE MILLIMETER AND ABOVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY THREE MILLIMETER AND ABOVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY THREE MILLIMETER AND ABOVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY THREE MILLIMETER AND ABOVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY EIGHTEEN TO TWENTY EIGHT MILLIMETER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY EIGHTEEN TO TWENTY EIGHT MILLIMETER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY EIGHTEEN TO TWENTY EIGHT MILLIMETER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY EIGHTEEN TO TWENTY EIGHT MILLIMETER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY EIGHTEEN TO TWENTY EIGHT MILLIMETER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY EIGHTEEN TO TWENTY EIGHT MILLIMETER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY GREATER THAN TWENTY EIGHT MILLIMETER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY GREATER THAN TWENTY EIGHT MILLIMETER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY GREATER THAN TWENTY EIGHT MILLIMETER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY GREATER THAN TWENTY EIGHT MILLIMETER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY GREATER THAN TWENTY EIGHT MILLIMETER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY GREATER THAN TWENTY EIGHT MILLIMETER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY LESS THAN EIGHTEEN MILLIMETER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY LESS THAN EIGHTEEN MILLIMETER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY LESS THAN EIGHTEEN MILLIMETER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY LESS THAN EIGHTEEN MILLIMETER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY LESS THAN EIGHTEEN MILLIMETER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY LESS THAN EIGHTEEN MILLIMETER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. AMERICAS RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 118. AMERICAS RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 119. AMERICAS RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 120. AMERICAS RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 121. AMERICAS RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2024 (USD MILLION)
  • TABLE 122. AMERICAS RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2025-2032 (USD MILLION)
  • TABLE 123. AMERICAS RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2024 (USD MILLION)
  • TABLE 124. AMERICAS RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2025-2032 (USD MILLION)
  • TABLE 125. AMERICAS RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2018-2024 (USD MILLION)
  • TABLE 126. AMERICAS RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2025-2032 (USD MILLION)
  • TABLE 127. AMERICAS RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 128. AMERICAS RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 129. AMERICAS RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2018-2024 (USD MILLION)
  • TABLE 130. AMERICAS RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2025-2032 (USD MILLION)
  • TABLE 131. AMERICAS RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2024 (USD MILLION)
  • TABLE 132. AMERICAS RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2025-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. NORTH AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 136. NORTH AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2024 (USD MILLION)
  • TABLE 138. NORTH AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2025-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2024 (USD MILLION)
  • TABLE 140. NORTH AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2025-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2018-2024 (USD MILLION)
  • TABLE 142. NORTH AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2025-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 144. NORTH AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2018-2024 (USD MILLION)
  • TABLE 146. NORTH AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2025-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2024 (USD MILLION)
  • TABLE 148. NORTH AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2025-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. LATIN AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 152. LATIN AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2024 (USD MILLION)
  • TABLE 154. LATIN AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2025-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2024 (USD MILLION)
  • TABLE 156. LATIN AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2025-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2018-2024 (USD MILLION)
  • TABLE 158. LATIN AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2025-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 160. LATIN AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2018-2024 (USD MILLION)
  • TABLE 162. LATIN AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2025-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2024 (USD MILLION)
  • TABLE 164. LATIN AMERICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2025-2032 (USD MILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2024 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2025-2032 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2024 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2025-2032 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2018-2024 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2025-2032 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2018-2024 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2025-2032 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2024 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2025-2032 (USD MILLION)
  • TABLE 181. EUROPE RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. EUROPE RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. EUROPE RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 184. EUROPE RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 185. EUROPE RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2024 (USD MILLION)
  • TABLE 186. EUROPE RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2025-2032 (USD MILLION)
  • TABLE 187. EUROPE RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2024 (USD MILLION)
  • TABLE 188. EUROPE RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2025-2032 (USD MILLION)
  • TABLE 189. EUROPE RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2018-2024 (USD MILLION)
  • TABLE 190. EUROPE RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2025-2032 (USD MILLION)
  • TABLE 191. EUROPE RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 192. EUROPE RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 193. EUROPE RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2018-2024 (USD MILLION)
  • TABLE 194. EUROPE RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2025-2032 (USD MILLION)
  • TABLE 195. EUROPE RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2024 (USD MILLION)
  • TABLE 196. EUROPE RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2025-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. MIDDLE EAST RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. MIDDLE EAST RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 200. MIDDLE EAST RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 201. MIDDLE EAST RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2024 (USD MILLION)
  • TABLE 202. MIDDLE EAST RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2025-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2024 (USD MILLION)
  • TABLE 204. MIDDLE EAST RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2025-2032 (USD MILLION)
  • TABLE 205. MIDDLE EAST RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2018-2024 (USD MILLION)
  • TABLE 206. MIDDLE EAST RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2025-2032 (USD MILLION)
  • TABLE 207. MIDDLE EAST RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 208. MIDDLE EAST RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2018-2024 (USD MILLION)
  • TABLE 210. MIDDLE EAST RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2025-2032 (USD MILLION)
  • TABLE 211. MIDDLE EAST RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2024 (USD MILLION)
  • TABLE 212. MIDDLE EAST RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2025-2032 (USD MILLION)
  • TABLE 213. AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 216. AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 217. AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2024 (USD MILLION)
  • TABLE 218. AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2025-2032 (USD MILLION)
  • TABLE 219. AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2024 (USD MILLION)
  • TABLE 220. AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2025-2032 (USD MILLION)
  • TABLE 221. AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2018-2024 (USD MILLION)
  • TABLE 222. AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2025-2032 (USD MILLION)
  • TABLE 223. AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 224. AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 225. AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2018-2024 (USD MILLION)
  • TABLE 226. AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2025-2032 (USD MILLION)
  • TABLE 227. AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2024 (USD MILLION)
  • TABLE 228. AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2025-2032 (USD MILLION)
  • TABLE 229. ASIA-PACIFIC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. ASIA-PACIFIC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. ASIA-PACIFIC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 232. ASIA-PACIFIC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 233. ASIA-PACIFIC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2024 (USD MILLION)
  • TABLE 234. ASIA-PACIFIC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2025-2032 (USD MILLION)
  • TABLE 235. ASIA-PACIFIC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2024 (USD MILLION)
  • TABLE 236. ASIA-PACIFIC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2025-2032 (USD MILLION)
  • TABLE 237. ASIA-PACIFIC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2018-2024 (USD MILLION)
  • TABLE 238. ASIA-PACIFIC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2025-2032 (USD MILLION)
  • TABLE 239. ASIA-PACIFIC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 240. ASIA-PACIFIC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 241. ASIA-PACIFIC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2018-2024 (USD MILLION)
  • TABLE 242. ASIA-PACIFIC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2025-2032 (USD MILLION)
  • TABLE 243. ASIA-PACIFIC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2024 (USD MILLION)
  • TABLE 244. ASIA-PACIFIC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 247. ASEAN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. ASEAN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. ASEAN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 250. ASEAN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 251. ASEAN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2024 (USD MILLION)
  • TABLE 252. ASEAN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2025-2032 (USD MILLION)
  • TABLE 253. ASEAN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2024 (USD MILLION)
  • TABLE 254. ASEAN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2025-2032 (USD MILLION)
  • TABLE 255. ASEAN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2018-2024 (USD MILLION)
  • TABLE 256. ASEAN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2025-2032 (USD MILLION)
  • TABLE 257. ASEAN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 258. ASEAN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 259. ASEAN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2018-2024 (USD MILLION)
  • TABLE 260. ASEAN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2025-2032 (USD MILLION)
  • TABLE 261. ASEAN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2024 (USD MILLION)
  • TABLE 262. ASEAN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2025-2032 (USD MILLION)
  • TABLE 263. GCC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. GCC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. GCC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 266. GCC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 267. GCC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2024 (USD MILLION)
  • TABLE 268. GCC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2025-2032 (USD MILLION)
  • TABLE 269. GCC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2024 (USD MILLION)
  • TABLE 270. GCC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2025-2032 (USD MILLION)
  • TABLE 271. GCC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2018-2024 (USD MILLION)
  • TABLE 272. GCC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2025-2032 (USD MILLION)
  • TABLE 273. GCC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 274. GCC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 275. GCC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2018-2024 (USD MILLION)
  • TABLE 276. GCC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2025-2032 (USD MILLION)
  • TABLE 277. GCC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2024 (USD MILLION)
  • TABLE 278. GCC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPEAN UNION RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPEAN UNION RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPEAN UNION RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPEAN UNION RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPEAN UNION RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPEAN UNION RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPEAN UNION RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPEAN UNION RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPEAN UNION RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPEAN UNION RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2025-2032 (USD MILLION)
  • TABLE 289. EUROPEAN UNION RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 290. EUROPEAN UNION RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 291. EUROPEAN UNION RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2018-2024 (USD MILLION)
  • TABLE 292. EUROPEAN UNION RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2025-2032 (USD MILLION)
  • TABLE 293. EUROPEAN UNION RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2024 (USD MILLION)
  • TABLE 294. EUROPEAN UNION RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2025-2032 (USD MILLION)
  • TABLE 295. BRICS RESORBABLE V